BACKGROUND: Activation of the NLRP3 inflammasome is associated with metabolic dysfunction, and intermittent fasting has been shown to improve clinical presentation of NLRP3 inflammasome-linked diseases. As mitochondrial perturbations, which function as a damage-associated molecular pattern, exacerbate NLRP3 inflammasome activation, we investigated whether fasting blunts inflammasome activation via sirtuin-mediated augmentation of mitochondrial integrity. METHODS: We performed a clinical study of 19 healthy volunteers. Each subject underwent a 24-hour fast and then was fed a fixed-calorie meal. Blood was drawn during the fasted and fed states and analyzed for NRLP3 inflammasome activation. We enrolled an additional group of 8 healthy volunteers to assess the effects of the sirtuin activator, nicotinamide riboside, on NLRP3 inflammasome activation. RESULTS: In the fasting/refeeding study, individuals showed less NLRP3 inflammasome activation in the fasted state compared with that in refed conditions. In a human macrophage line, depletion of the mitochondrial-enriched sirtuin deacetylase SIRT3 increased NLRP3 inflammasome activation in association with excessive mitochondrial ROS production. Furthermore, genetic and pharmacologic SIRT3 activation blunted NLRP3 activity in parallel with enhanced mitochondrial function in cultured cells and in leukocytes extracted from healthy volunteers and from refed individuals but not in those collected during fasting. CONCLUSIONS: Together, our data indicate that nutrient levels regulate the NLRP3 inflammasome, in part through SIRT3-mediated mitochondrial homeostatic control. Moreover, these results suggest that deacetylase-dependent inflammasome attenuation may be amenable to targeting in human disease. TRIAL REGISTRATION: ClinicalTrials.gov NCT02122575 and NCT00442195. FUNDING: Division of Intramural Research, NHLBI of the NIH.
BACKGROUND: Activation of the NLRP3 inflammasome is associated with metabolic dysfunction, and intermittent fasting has been shown to improve clinical presentation of NLRP3inflammasome-linked diseases. As mitochondrial perturbations, which function as a damage-associated molecular pattern, exacerbate NLRP3 inflammasome activation, we investigated whether fasting blunts inflammasome activation via sirtuin-mediated augmentation of mitochondrial integrity. METHODS: We performed a clinical study of 19 healthy volunteers. Each subject underwent a 24-hour fast and then was fed a fixed-calorie meal. Blood was drawn during the fasted and fed states and analyzed for NRLP3 inflammasome activation. We enrolled an additional group of 8 healthy volunteers to assess the effects of the sirtuin activator, nicotinamide riboside, on NLRP3 inflammasome activation. RESULTS: In the fasting/refeeding study, individuals showed less NLRP3 inflammasome activation in the fasted state compared with that in refed conditions. In a human macrophage line, depletion of the mitochondrial-enriched sirtuin deacetylase SIRT3 increased NLRP3 inflammasome activation in association with excessive mitochondrial ROS production. Furthermore, genetic and pharmacologic SIRT3 activation blunted NLRP3 activity in parallel with enhanced mitochondrial function in cultured cells and in leukocytes extracted from healthy volunteers and from refed individuals but not in those collected during fasting. CONCLUSIONS: Together, our data indicate that nutrient levels regulate the NLRP3 inflammasome, in part through SIRT3-mediated mitochondrial homeostatic control. Moreover, these results suggest that deacetylase-dependent inflammasome attenuation may be amenable to targeting in human disease. TRIAL REGISTRATION: ClinicalTrials.gov NCT02122575 and NCT00442195. FUNDING: Division of Intramural Research, NHLBI of the NIH.
Authors: James B Johnson; Warren Summer; Roy G Cutler; Bronwen Martin; Dong-Hoon Hyun; Vishwa D Dixit; Michelle Pearson; Matthew Nassar; Richard Telljohann; Richard Tellejohan; Stuart Maudsley; Olga Carlson; Sujit John; Donald R Laub; Mark P Mattson Journal: Free Radic Biol Med Date: 2006-12-14 Impact factor: 7.376
Authors: Agnieszka A Kendrick; Mahua Choudhury; Shaikh M Rahman; Carrie E McCurdy; Marisa Friederich; Johan L K Van Hove; Peter A Watson; Nicholas Birdsey; Jianjun Bao; David Gius; Michael N Sack; Enxuan Jing; C Ronald Kahn; Jacob E Friedman; Karen R Jonscher Journal: Biochem J Date: 2011-02-01 Impact factor: 3.857
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Yan Qu; Shahram Misaghi; Kim Newton; Laurie L Gilmour; Salina Louie; James E Cupp; George R Dubyak; David Hackos; Vishva M Dixit Journal: J Immunol Date: 2011-04-20 Impact factor: 5.422
Authors: Kiichi Nakahira; Jeffrey Adam Haspel; Vijay A K Rathinam; Seon-Jin Lee; Tamas Dolinay; Hilaire C Lam; Joshua A Englert; Marlene Rabinovitch; Manuela Cernadas; Hong Pyo Kim; Katherine A Fitzgerald; Stefan W Ryter; Augustine M K Choi Journal: Nat Immunol Date: 2010-12-12 Impact factor: 25.606
Authors: Ariel C Bulua; Anna Simon; Ravikanth Maddipati; Martin Pelletier; Heiyoung Park; Kye-Young Kim; Michael N Sack; Daniel L Kastner; Richard M Siegel Journal: J Exp Med Date: 2011-01-31 Impact factor: 14.307
Authors: Sara C Sebag; Olha M Koval; John D Paschke; Christopher J Winters; Omar A Jaffer; Ryszard Dworski; Fayyaz S Sutterwala; Mark E Anderson; Isabella M Grumbach Journal: JCI Insight Date: 2017-02-09
Authors: Albert E Towers; Maci L Oelschlager; Jay Patel; Stephen J Gainey; Robert H McCusker; Gregory G Freund Journal: Metabolism Date: 2017-03-09 Impact factor: 8.694
Authors: Dongryeol Ryu; Hongbo Zhang; Eduardo R Ropelle; Vincenzo Sorrentino; Davi A G Mázala; Laurent Mouchiroud; Philip L Marshall; Matthew D Campbell; Amir Safi Ali; Gary M Knowels; Stéphanie Bellemin; Shama R Iyer; Xu Wang; Karim Gariani; Anthony A Sauve; Carles Cantó; Kevin E Conley; Ludivine Walter; Richard M Lovering; Eva R Chin; Bernard J Jasmin; David J Marcinek; Keir J Menzies; Johan Auwerx Journal: Sci Transl Med Date: 2016-10-19 Impact factor: 17.956